References
- AOYAMA, T., YAMANO, S., WAXMAN, D. J., LAPENSON, D. P., MEYER, U. A., FISCHER, V., TYNDALE, R., INABA, T., KALOW, W., GELBOIN, H. V. and GONZALEZ, F. J., 1989, Cytochrome P450 hPCN3, a novel cytochrome P-450 Ma gene product that is differentially expressed in adult human liver. Journal of Biological Chemistry, 264, 10388–10395.
- BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., ÄYRTON, A. D., CLARKE, S. E. and CHENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica, 25, 261–270.
- DECKERS, G. H., SCHOONEN, W. G. and KLOOSTERBOER, H. J., 1992, Receptor binding and biological studies with norethisterone derivatives. In Proceedings of the 74th Annual Meeting of the Endocrine Society (Bethesda: Endocrine Society), p. 234.
- GENTILE, D. M., VERHOEVEN, C. H. J., SHIMADA, T. and BACK, D. J., 1998, The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. Journal of Pharmacology and Experimental Therapeutics, 287, 975–982.
- GUENGERICH, F. P., 1996, In vitro techniques for studying drug metabolism. Journal of Pharmacokinetks and Biopharmacology, 24, 521–533.
- HUNT, C. M., WATKINS, P. B., SAENGER, P., STAVE, G. M., BARLASCINI, N., WATLINGTON, C. 0., WRIGHT, J. T. and GUZELIAN, P. S., 1992, Heterogeneity of CYP3A isoforms metabolizing erythomycin and cortisol. Clinical Pharmacology and Therapeutics, 51, 18–23.
- Li, A. P., KAMINSKI, D. L. and RASMUSSSEN, A, 1995, Substrates of human hepatic cytochrome P450 3A4. Toxicology, 104, 1–8.
- LOWRY, 0. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
- OMURA, T. and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. Journal of Biological Chemistry, 239, 2370–2378.
- SCHMIDER, J., GREENBLATT', D. J., MOLTKE, L. L. V, KARSOV, D., VENA, R., FRIEDMAN, H. L. and SHADER, R. I., 1997, Biotransformation of mestranol to ethinyl oestradiol in vitro: the role of Cytochrome P-450 2C9 and metabolic inhibitors. Journal of Clinical Pharmacology, 37, 193–200.
- SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variation in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414–423.
- VERHOEVEN, C. H. J., KREBBERS, S. F. M., WAGENAARS, G. N., BOOY, C. J., GROOTHUIS, G. M. M., OLINGA, P. and Vos, R. M. E., 1998, The in vitro and in vivo metabolism of the progestagen Org 30659 in several species. Drug Metabolism and Disposition, 26, 1102–1112.
- WAXMAN, D. J., ÄTTISANO, C., GUENGERICH, F. P. and LAPENSON, D. P., 1988, Human liver microsomal steroid metabolism: Identification of the major microsomal steroid hormone 6[3-hydroxylase cytochrome P450 enzyme. Archives of Biochemistry and Biophysics, 263, 424–436.
- WILKINSON, G. R., 1996, Cytochrome P4503A (CYP3A) metabolism: prediction of the in vivo activity in humans. Journal of Pharmacokinetics and Biopharmacology, 24, 475–490.
- WRIGHTON, S. A., RING, B. J., WATKINS, P. B. and VANDENBRANDEN, M., 1989, Identification of a polymorphically expressed member of the human cytochrome P450III Family. Molecular Pharmacology, 36, 97–105.
- WRIGirroN, S. A., VANDENBRANDEN, M. and RING, B. J., 1996, The human drug metabolizing cytochromes P450. Journal of Pharmacokinetics and Biopharmacology, 24, 461–473.
- YAMAZAKI, H. and SHIMADA, T., 1997, Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9 and 3A4 in human liver microsomes. Archives of Biochemistry and Biophysics, 346, 161–169.